News & Events

World leading manufacturer of recombinant human albumin

  • Contact
  • Albumin
    • Albumin
    • Recombumin® products
    • Sample page
  • Solutions
    • Recombumin® products
    • Compliance services
    • Innovation services
    • Veltis technology
  • Applications
    • Cell therapy
    • Gene therapy
    • Vaccine stabilization
    • Medical device coating
    • Protein & peptide formulation
    • Covid-19
  • About
    • About Albumedix
    • Management
    • Partnering
      • R&D collaborations
      • Pipeline
    • Careers
    • CSR
    • FAQ
  • Media
    • Scientific Library
    • News & Events
    • Blog
Albumedix Media News & Events Cell & Gene Meeting on the Mesa 2023

Cell & Gene Meeting on the Mesa 2023

10 Oct 2023

From 10th – 12th October 2023, the Cell & Gene Meeting on the Mesa conference will be delivered digitally. Organised by the Alliance for Regenerative Medicine, the conference is set to ‘Tackling the commercialization hurdles facing the cell and gene therapy sector today, this meeting covers a wide range of topics from clinical trial design to alternative payment models to scale-up and supply chain platforms for advanced therapies.’

Albumedix believes in empowering excellence to enable advanced therapies and unstable drug candidates to reach patients worldwide. To learn more about the benefits our recombinant human albumin could bring to your advanced therapy, make sure to book a partnering meeting with one of our expert representatives.

CONTACT

Albumedix Ltd.
Mabel Street
The Meadows
Nottingham
NG2 3ED, United Kingdom
Tel: +44 115 9553379
info@albumedix.com

 

Albumedix - Dedicated to Better Health

Albumedix is a science-driven company and recognized leader of best-in-class albumin-enabled solutions. Established in the UK in 1984, with a mission to empower excellence, Albumedix has supported its life-science partners to deliver hundreds of million safe doses of clinical and marketed therapeutics, globally. Albumedix’ solutions include the world’s only USP-NF compliant recombinant human albumin (Recombumin®), client-centric development and compliance services and drug-enhancing technologies (Veltis®). By always striving for more and collaboratively challenging status quo, Albumedix enables the development and commercialisation of advanced therapies and next-generation biopharmaceuticals to the benefit of people worldwide.

 

Privacy | Cookies | Patent Portfolio

ALBUMEDIX, the ALBUMEDIX LOGO, DEDICATED TO BETTER HEALTH and marks such as RECOMBUMIN and VELTIS are trademarks of Albumedix. Albumedix© Copyright 2018

FOLLOW US

  • Albumin
    • Albumin
    • Recombumin® products
    • Sample page
  • Solutions
    • Recombumin® products
    • Compliance services
    • Innovation services
    • Veltis technology
  • Applications
    • Cell therapy
    • Gene therapy
    • Vaccine stabilization
    • Medical device coating
    • Protein & peptide formulation
    • Covid-19
  • About
    • About Albumedix
    • Management
    • Partnering
      • R&D collaborations
      • Pipeline
    • Careers
    • CSR
    • FAQ
  • Media
    • Scientific Library
    • News & Events
    • Blog

We use cookies on our website to improve the website and your experience.

Read more